Gut microbiota‑metabolism‑immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy characterized by complex metabolic dysregulation and immune evasion mechanisms, leading to poor prognosis and limited treatment efficacy.
The abstract discusses the role of the gut‑liver axis and how traditional Chinese medicine (TCM) can modulate gut microbiota, metabolites, and immune responses to treat hepatocellular carcinoma (HCC).
The sentence reflects the core challenge in HCC: aggressive biology and limited therapeutic options, highlighting the need to explore novel mechanisms such as gut microbiota and traditional Chinese medicine for treatment.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort